Treatment of clinical stage I germ cell tumors

Urology

Volumn 59, Issue 2, 2002, Pages 173-179

  Chang, Sam S ^a   Roth, Bruce ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; GERM CELL TUMOR; HUMAN; LYMPH NODE; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SEMINOMA; SURVIVAL; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; GERMINOMA; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; RADIOTHERAPY; RETROPERITONEAL SPACE; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 0036169914     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01532-1     Document Type: Review

References (49)

1. Surveillance for stage I testicular seminoma; is it a good option?
2. The management of stage I testis cancer
3. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer
4. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors
5. A rational approach to managing stage I nonseminomatous germ cell cancer
6. Staging of testis cancer; combining serum markers, histologic parameters, and radiographic imaging
7. Medical Research Council prospective study of surveillance for stage I testicular teratoma
8. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors
9. Management of low clinical stage testis cancer
10. Clinical stage I testis cancer; long-term outcome of patients on surveillance
11. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer
12. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis
13. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease; a combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment
14. Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumors; clinical correlation in stage I disease
15. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors
16. Clinical stage I nonseminoma; surgery versus surveillance
17. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer; a review of the Indiana University experience (1965-1989)
18. Late relapse of testicular cancer
19. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors; A Southeastern Cancer Study Group protocol
20. Role of surgery in management of germ cell tumor
21. Retroperitoneal lymphadenectomy in staging and treatment; the development of nerve-sparing techniques
22. Staging relationships and outcome in early stage testicular cancer; a report from the testicular cancer intergroup study
23. Complications of therapy for testicular cancer
24. Complications of primary retroperitoneal lymph node dissection
25. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma; long-term outcome
26. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors
27. Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors; late relapse may occur
28. Orchiectomy alone in clinical stage I nonseminomatous testis cancer; a critical appraisal
29. How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?
30. Accuracy of preoperative staging in stage A and B non-seminomatous germ cell testis tumors
31. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis; a Medical Research Council report
32. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors
33. Analysis of risk factors for cisplatin induced ototoxicity in patients with testicular cancer
34. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
35. Treatment-associated leukemia following testicular cancer
36. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment
37. Radiation therapy for early stage seminoma of the testis; analysis of survival and gastrointestinal toxicity in patients treated with modern megavoltage techniques over 10 years
38. Risk of second non-germ cell cancer after treatment of stage I-II testicular seminoma
39. Second malignancies following pure seminoma
40. Optimal planning target volume for stage I testicular seminoma; a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group
41. Radiotherapy for stages I and IIA/B testicular seminoma
42. Therapeutic strategy in stage I seminomas; which lymph node areas are to be irradiated?
43. Long term outcome and cost in the management of stage I testicular seminoma
44. Surveillance following orchidectomy for stage I seminoma of the testis
45. Surveillance following orchidectomy for state I testicular seminoma
46. Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma
47. Adjuvant radiation versus observation; a cost analysis of alternate management schemes in early-stage testicular seminoma
48. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma; should it be tested in a randomized trial against radiotherapy?
49. Quality of life after laparoscopic versus open retroperitoneal lymphadenectomy for testicular tumor-the patients' view